Physician profile
Thomas E Sharon
NPI 1154384188
$5,954.03
in general payments reported to CMS, 2019-2025
55 companies · $911 in 2025
The $911 reported for 2025 was more than what 90% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $856 · 2020: $716 · 2021: $1,173 · 2022: $919 · 2023: $685 · 2024: $694 · 2025: $911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,289.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $932.95 | 2019-2024 | Lo Loestrin Fe, Ubrelvy |
| Astellas Pharma US INC | $467.48 | 2019-2024 | Veozah, Myrbetriq |
| Organon LLC | $466.04 | 2021-2025 | Nexplanon, Jada System |
| Pfizer INC. | $313.50 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $286.14 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $202.17 | 2023-2025 | Myfembree, Gemtesa |
| Aspira Women'S Health INC | $198.55 | 2022 | |
| Exeltis, USA INC. | $182.32 | 2020-2025 | Slynd |
| Allergan, INC. | $177.05 | 2019-2020 | |
| Evofem Biosciences, INC. | $169.47 | 2023-2025 | Phexxi, Solosec, Phexx |
| Agile Therapeutics, INC. | $145.60 | 2021-2024 | Twirla |
| Coopersurgical, INC. | $144.30 | 2020-2023 | Paragard T 380a, Summit Doppler |
| Merck Sharp & Dohme LLC | $136.80 | 2019-2021 | |
| Biogen, INC. | $136.31 | 2024-2025 | Zurzuvae |
| Amgen INC. | $127.55 | 2019-2025 | Evenity |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Sharon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.